Boulos & Cooper Pharmaceuticals

Boulos & Cooper Pharmaceuticals is an Australian biopharmaceutical company dedicated to the discovery and development of novel antibiotics to treat life-threatening bacterial infections. The company's primary focus is its lead candidate, Ramizol, a first-in-class styrylbenzene derivative designed to treat Clostridioides difficile infections and other Gram-positive pathogens. Ramizol has demonstrated a unique mechanism of action that targets the bacterial cell membrane and inhibits essential biosynthetic processes, minimizing the risk of resistance development. Boulos & Cooper Pharmaceuticals operates out of Perth, Western Australia, and has successfully advanced its lead program through Phase 1 clinical trials.